



WEALTH WEEKLY

Weekly Alerts You Can Use!

Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	24039	23501	24359	23032	24051	23722-24355	Buy between 23922-23944 zone. Targets at 24175/24359. Stop at 23498.
BANK NIFTY	54664	52851	56500	50416	51084	53200-55991	Buy at CMP. Targets at 56251/57100. Stop 52800.

Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
SUNPHARMA	1787	1553	1901	1698	1768	Positive	Incorporated in the year 1993, Sun Pharmaceutical is the fourth largest specialty generic pharmaceutical company in the world with global revenues of US\$ 5.8 billion. In the US, Sun Pharma is amongst the leading generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market. Sun Pharma's broad portfolio consists of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids trusted by healthcare professionals and patients, to more than 100 countries across the globe. Technically, the stock at the moment is witnessing massive bullish breakout on the upside with major hurdles at its all-time-high at 1960 area, now above 1960-mark, momentum buying is quite likely. Preferred Strategy: Establish long positions at CMP, targeting 1901/1961 and then aggressive targets at psychological 2100 mark. Stop below 1553. Holding Period: 9-12 Months.

BUY SUNPHARMA CMP 1787, Target 1901

CMP	1787
Target Price	1901
52 Week H/L	1960.2/1376.75
P/E	136.11
EPS (TTM)	13.13
Promoter Holding/DIIs/FIIs	54.48/36.7/18
Book Value	103.25
Market Cap (INR)	4,28,725.17 crores

Theme:

Incorporated in the year 1993, Sun Pharmaceutical is the fourth largest specialty generic pharmaceutical company in the world with global revenues of US\$ 5.8 billion. Sun Pharma is the largest pharmaceutical company in India.

Supported by 41 manufacturing facilities, the firm markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Sun Pharma's broad portfolio consists of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Every year, Sun Pharma sells over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.

In the US, Sun Pharma is amongst the leading generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market.

We are the largest Indian company in emerging markets with a presence in over 80 markets. Brazil, Mexico, Russia, Romania and South Africa are some of our key emerging markets.

Also is present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others.

Our presence in emerging markets and the developing world enables our teams to cross-sell and build brands with ease.

The biggest positive catalyst continues to be a bigger-than-expected recent quarterly profit for the third quarter that ended December 31, 2024 which was primarily aided by strong sales in the domestic market.

The consolidated net profit rose 15% to Rs 2,903 crore (\$335.3 million) in the third quarter with sales in India, Sun Pharma's largest revenue-generating region, rose 14% to Rs 4,300 crore, or about 31% of total sales. That was bigger than the 11% increase in the previous quarter.

EBITDA surged 25% to ₹4,192.2 crore and the EBITDA margin stood at 30.7% in the reporting quarter compared to 27.1% in the year-ago period.

Its high-margin global specialty pharmaceutical segment, which includes medicines for conditions such as alopecia and psoriasis, reported a 17.5% jump in sales to \$370 million, or 21% of total sales.

Technical Outlook: The stock at the moment is witnessing massive bullish breakout on the upside on the long-term charts and that's on backdrop of one way up move since March 2025 low at Rs 1553.

Major supports are placed at 1721/1660 zone. The stocks 200-dma is at 1768 area. The stock faces major hurdles at its all-time-high at 1960 area, now above 1960-mark, momentum buying is quite likely.

Preferred Strategy: Establish long positions at CMP, targeting 1901/1961 and then aggressive targets at psychological 2100 mark. Stop below 1553. Holding Period: 9-12 Months.

Daily Chart of SUNPHARMA :



Mehta Equities

903 Lodha Supremus, Dr. E Moses Road, Worli Naka, Mumbai - 400 018 Board: +91-22-61507100/101 Fax: +91-22-61507102

Disclosures and Disclaimer : This report must be read with the disclosures in the Disclosure appendix, and with the Disclaimer, which forms part of it. This document does not contain any investment views or opinions.

Rewarding Relationships

www.mehtagroup.in